Angina Market Report 2026

The angina market size has grown strongly in recent years. It will grow from $11.36 billion in 2025 to $12.05 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to rising prevalence of cardiovascular diseases, availability of beta blockers and nitrates, expansion of hospital cardiac care units, increased diagnostic testing, growth of cardiology specialty care.

The angina market size is expected to see strong growth in the next few years. It will grow to $14.84 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to growing demand for personalized cardiovascular treatment, increasing use of minimally invasive cardiac procedures, rising adoption of digital cardiac monitoring, expansion of preventive cardiology programs, advancements in cardiovascular drug development. Major trends in the forecast period include increasing adoption of combination drug therapies, rising use of long-acting nitrates, growing focus on preventive cardiac care, expansion of interventional treatment options, enhanced emphasis on lifestyle and risk management.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the angina market in the coming years. Cardiovascular diseases are conditions affecting the heart and blood vessels, including coronary heart disease, heart failure, and stroke. The rise in cardiovascular diseases is primarily attributed to aging populations and greater exposure to modifiable risk factors such as unhealthy diets, physical inactivity, and tobacco use. This growing prevalence of cardiovascular diseases fuels the demand for angina treatments, as these conditions often present with chest pain that requires medical intervention to alleviate symptoms and prevent complications. For example, in October 2024, the Centers for Disease Control and Prevention, a US-based government agency monitoring public health, reported that cardiovascular disease deaths rose from 371,506 cases in 2022 to 919,032 deaths in 2023. Consequently, the rising prevalence of cardiovascular diseases is supporting the expansion of the angina market.

Major companies operating in the angina market are focusing on developing innovative drugs such as metoprolol tartrate tablets to offer more effective and targeted treatments for patients with coronary artery disease (CAD) and associated conditions. Metoprolol tartrate tablets are commonly prescribed to manage various cardiovascular issues, including angina (chest pain), hypertension (high blood pressure), and heart failure. For example, in April 2023, Zydus, an India-based pharmaceutical company, received final approval from the United States Food and Drug Administration (US-FDA) to manufacture and market its generic version of Metoprolol Tartrate Tablets USP in 25 mg, 50 mg, and 100 mg strengths. Metoprolol is a beta blocker used to treat a range of cardiovascular conditions, including hypertension and angina, and to enhance survival following a heart attack.

In March 2024, Novo Nordisk, a Denmark-based healthcare company, acquired Cardior Pharmaceuticals for $1.1 billion (€1.025 billion). The acquisition is intended to enhance Novo Nordisk's pipeline in cardiovascular disease management by integrating Cardior's RNA-based therapeutics, especially CDR132L, which is currently in Phase II clinical trials for the treatment of heart failure. Cardior Pharmaceuticals is a Germany-based company that provides angiotensin-converting enzyme inhibitors.

Major companies operating in the angina market are Pfizer Inc., Bayer AG, AstraZeneca PLC, Merck & Co Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Otsuka Pharmaceutical Co Ltd, Bristol‑Myers Squibb Company, Boehringer Ingelheim GmbH, Abbott Laboratories, Daiichi Sankyo Company Ltd, Takeda Pharmaceutical Company Limited, Cipla Limited, Sun Pharmaceutical Industries Ltd, Zydus Cadila Healthcare Ltd, Astellas Pharma Inc., Amarin Corporation, Torrent Pharmaceuticals Ltd.

North America was the largest region in the angina market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the angina market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the angina market by increasing costs of imported active pharmaceutical ingredients, cardiovascular drugs, medical devices, and interventional cardiology equipment. Healthcare providers in North America and Europe are most impacted due to reliance on global pharmaceutical supply chains, while Asia-Pacific faces cost pressure on generic drug manufacturing inputs. These tariffs are contributing to higher treatment and procedure costs. However, they are also encouraging domestic drug production, regional sourcing of medical supplies, and long-term investment in localized cardiovascular healthcare manufacturing.

The angina market research report is one of a series of new reports that provides angina market statistics, including angina industry global market size, regional shares, competitors with a angina market share, detailed angina market segments, market trends and opportunities, and any further data you may need to thrive in the angina industry. This angina market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Angina, also called angina pectoris, is a medical condition marked by chest pain or discomfort, generally caused by reduced blood flow to the heart muscle. This insufficient blood flow is typically due to blockages or narrowing of the coronary arteries resulting from atherosclerosis.

The main types of angina include angina pectoris, unstable angina, prinzmetal angina, and others. Angina pectoris, a condition linked to coronary heart disease, presents as chest discomfort or pain resulting from an inadequate blood supply to the heart, often caused by blockages in the heart's arteries. The various treatment options include lifestyle modifications, medications, angioplasty and stenting, coronary bypass surgery, and others, with different drug classes such as beta-blockers, nitrates, calcium channel blockers, angiotensin-converting enzyme inhibitors, and other medications that are utilized in multiple settings including clinics, hospitals, and more.

The angina market consists of revenues earned by entities by providing treatments for stable angina, and microvascular angina. The market value includes the value of related goods sold by the service provider or included within the service offering. The angina market also includes sales of anticoagulants and statins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.